Should You Buy Vertex Pharmaceuticals Stock Hand Over Fist Before Jan. 30?
Vertex Pharmaceuticals ( VRTX 3.06%) might be one of those special cases. Should you buy Vertex stock hand over fist before Jan. 30? What's so special about Jan. 30 for Vertex? It's the PDUFA action date set by the U.S. Food and Drug Administration (FDA) for making an approval decision on suzetrigine in treating acute pain.
Wells Fargo & Company Has Lowered Expectations for Vertex Pharmaceuticals (NASDAQ:VRTX) Stock Price
Vertex Pharmaceuticals (NASDAQ:VRTX – Get Free Report) had its price objective cut by Wells Fargo & Company from $555.00 to $460.00 in a report issued on Friday,Benzinga reports. The brokerage currently has an “overweight” rating on the pharmaceutical company’s stock.
David Jagielski (Eli Lilly): It may look as though Eli Lilly's stock has peaked given its recent slide, but there's still a lot more room for it to run higher. Vertex Pharmaceuticals (NASDAQ ...
Jefferies analyst Michael Yee has maintained their bullish stance on VRTX stock, giving a Buy rating today.Stay Ahead of the Market:Discover ...
Vertex Pharmaceuticals (VRTX ... correlation between trends in earnings estimate revisions and near-term stock price movements. Vertex is expected to post earnings of $4 per share for the ...
Vertex Pharmaceuticals Inc. closed 18.39% short of its 52-week high of $519.88, which the company reached on November 8th.
Morgan Stanley analyst Terence Flynn maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research Report) today and set a price target ...
Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback